Showing results (71-80 of 84) with videos related to
Sort By:
Pageof 9
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|April 15, 2015
SI113, a specific inhibitor of the Sgk1 kinase activity that counteracts cancer cell proliferationLucia D'Antona, Rosario Amato, Cristina Talarico, et al.Plos One|July 14, 2012
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsValeria Cento, Carmen Mirabelli, Romina Salpini, et al.The Journal of Antimicrobial Chemotherapy|May 21, 2013
Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimenClaudia Alteri, Anna Artese, Gertjan Beheydt, et al.Chemmedchem|September 29, 2011
Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirineStefano Alcaro, Claudia Alteri, Anna Artese, et al.Journal of Medical Virology|March 26, 2018
Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modelingNadia Marascio, Grazia Pavia, Isabella Romeo, et al.Chemical Biology & Drug Design|August 14, 2018
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T)Lydia Pouga, Maria Mercedes Santoro, Charlotte Charpentier, et al.Journal of Experimental & Clinical Cancer Research : CR|March 26, 2023
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myelomaFrancesca Scionti, Giada Juli, Roberta Rocca, et al.ACS Chemical Neuroscience|March 5, 2016
Design and Synthesis of New Transient Receptor Potential Vanilloid Type-1 (TRPV1) Channel Modulators: Identification, Molecular Modeling Analysis, and Pharmacological Characterization of the N-(4-Hydroxy-3-methoxybenzyl)-4-(thiophen-2-yl)butanamide, a Small Molecule Endowed with Agonist TRPV1 Activity and Protective Effects against Oxidative StressFrancesca Aiello, Mariateresa Badolato, Federica Pessina, et al.Journal of Medicinal Chemistry|May 16, 2023
In Silico-Guided Rational Drug Design and Synthesis of Novel 4-(Thiophen-2-yl)butanamides as Potent and Selective TRPV1 AgonistsIsabella Romeo, Antonella Brizzi, Federica Pessina, et al.ACS Chemical Biology|May 1, 2013
Discovery of PTPRJ agonist peptides that effectively inhibit in vitro cancer cell proliferation and tube formationFrancesco Ortuso, Francesco Paduano, Alfonso Carotenuto, et al.Pageof 9